ImmunoCellular Therapeutics Ltd
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokin… Read more
ImmunoCellular Therapeutics Ltd (IMUC) - Total Liabilities
Latest total liabilities as of December 2022: $4.96 Million USD
Based on the latest financial reports, ImmunoCellular Therapeutics Ltd (IMUC) has total liabilities worth $4.96 Million USD as of December 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ImmunoCellular Therapeutics Ltd - Total Liabilities Trend (2005–2024)
This chart illustrates how ImmunoCellular Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ImmunoCellular Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of ImmunoCellular Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suny Cellular Communication Ltd
TA:SNCM
|
Israel | ILA228.64 Million |
|
Thiensurat Public Company Limited
BK:TSR
|
Thailand | ฿1.95 Billion |
|
Captivision Inc. Warrant
NASDAQ:CAPTW
|
USA | $80.62 Million |
|
Teras Resources Inc
PINK:TRARF
|
USA | $683.13K |
|
Cinis Fertilizer AB
ST:CINIS
|
Sweden | Skr624.80 Million |
|
Tijaria Polypipes Limited
NSE:TIJARIA
|
India | ₹822.42 Million |
|
BDCC
PINK:BDCC
|
USA | $949.90K |
|
ReTo Eco-Solutions Inc
NASDAQ:RETO
|
USA | $7.19 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down ImmunoCellular Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImmunoCellular Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImmunoCellular Therapeutics Ltd (2005–2024)
The table below shows the annual total liabilities of ImmunoCellular Therapeutics Ltd from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.01 Million | -83.49% |
| 2023-12-31 | $6.10 Million | +23.09% |
| 2022-12-31 | $4.96 Million | +51.04% |
| 2021-12-31 | $3.28 Million | +2293.47% |
| 2020-12-31 | $137.13K | -94.19% |
| 2017-12-31 | $2.36 Million | -78.06% |
| 2016-12-31 | $10.76 Million | +28.66% |
| 2015-12-31 | $8.36 Million | +343.16% |
| 2014-12-31 | $1.89 Million | -23.52% |
| 2013-12-31 | $2.47 Million | -37.56% |
| 2012-12-31 | $3.95 Million | +0.83% |
| 2011-12-31 | $3.92 Million | +29.36% |
| 2010-12-31 | $3.03 Million | +706.27% |
| 2009-12-31 | $375.72K | +99.80% |
| 2008-12-31 | $188.05K | +158.46% |
| 2007-12-31 | $72.75K | -91.73% |
| 2006-12-31 | $880.18K | -36.17% |
| 2005-12-31 | $1.38 Million | -- |